Literature DB >> 28857715

Predictive factors of flares in systemic lupus erythematosus patients: data from a multiethnic Latin American cohort.

M F Ugarte-Gil1,2, D Wojdyla3, C A Pastor-Asurza1,4, R V Gamboa-Cárdenas1, E M Acevedo-Vásquez1,4, L J Catoggio5, M A García6, E Bonfá7, E I Sato8, L Massardo9, V Pascual-Ramos10, L A Barile11, G Reyes-Llerena12, A Iglesias-Gamarra13, J F Molina-Restrepo14, R Chacón-Díaz15, G S Alarcón16, B A Pons-Estel17.   

Abstract

Purpose The purpose of this paper is to determine the factors predictive of flares in systemic lupus erythematosus (SLE) patients. Methods A case-control study nested within the Grupo Latino Americano De Estudio de Lupus (GLADEL) cohort was conducted. Flare was defined as an increase ≥4 points in the SLEDAI. Cases were defined as patients with at least one flare. Controls were selected by matching cases by length of follow-up. Demographic and clinical manifestations were systematically recorded by a common protocol. Glucocorticoid use was recorded as average daily dose of prednisone and antimalarial use as percentage of time on antimalarial and categorized as never (0%), rarely (>0-25%), occasionally (>25%-50%), commonly (˃50%-75%) and frequently (˃75%). Immunosuppressive drugs were recorded as used or not used. The association between demographic, clinical manifestations, therapy and flares was examined using univariable and multivariable conditional logistic regression models. Results A total of 465 cases and controls were included. Mean age at diagnosis among cases and controls was 27.5 vs 29.9 years, p = 0.003; gender and ethnic distributions were comparable among both groups and so was the baseline SLEDAI. Independent factors protective of flares identified by multivariable analysis were older age at diagnosis (OR = 0.929 per every five years, 95% CI 0.869-0.975; p = 0.004) and antimalarial use (frequently vs never, OR = 0.722, 95% CI 0.522-0.998; p = 0.049) whereas azathioprine use (OR = 1.820, 95% CI 1.309-2.531; p < 0.001) and SLEDAI post-baseline were predictive of them (OR = 1.034, 95% CI 1.005-1.064; p = 0.022). Conclusions In this large, longitudinal Latin American cohort, older age at diagnosis and more frequent antimalarial use were protective whereas azathioprine use and higher disease activity were predictive of flares.

Entities:  

Keywords:  Systemic lupus erythematosus; antimalarials; flares; risk factors

Mesh:

Substances:

Year:  2017        PMID: 28857715     DOI: 10.1177/0961203317728810

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  4 in total

1.  Outcomes of Systemic Lupus Erythematosus in Patients who Discontinue Hydroxychloroquine.

Authors:  Z Aouhab; H Hong; C Felicelli; S Tarplin; R A Ostrowski
Journal:  ACR Open Rheumatol       Date:  2019-10-18

2.  Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.

Authors:  Celline C Almeida-Brasil; John G Hanly; Murray Urowitz; Ann Elaine Clarke; Guillermo Ruiz-Irastorza; Caroline Gordon; Rosalind Ramsey-Goldman; Michelle Petri; Ellen M Ginzler; D J Wallace; Sang-Cheol Bae; Juanita Romero-Diaz; Mary Anne Dooley; Christine Peschken; David Isenberg; Anisur Rahman; Susan Manzi; Søren Jacobsen; Sam Lim; Ronald F van Vollenhoven; Ola Nived; Andreas Jönsen; Diane L Kamen; Cynthia Aranow; Jorge Sanchez-Guerrero; Dafna D Gladman; Paul R Fortin; Graciela S Alarcón; Joan T Merrill; Kenneth Kalunian; Manuel Ramos-Casals; Kristján Steinsson; Asad Zoma; Anca Askanase; Munther A Khamashta; Ian N Bruce; Murat Inanc; Michal Abrahamowicz; Sasha Bernatsky
Journal:  Ann Rheum Dis       Date:  2021-12-15       Impact factor: 27.973

3.  First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR).

Authors:  Bernardo A Pons-Estel; Eloisa Bonfa; Enrique R Soriano; Mario H Cardiel; Ariel Izcovich; Federico Popoff; Juan M Criniti; Gloria Vásquez; Loreto Massardo; Margarita Duarte; Leonor A Barile-Fabris; Mercedes A García; Mary-Carmen Amigo; Graciela Espada; Luis J Catoggio; Emilia Inoue Sato; Roger A Levy; Eduardo M Acevedo Vásquez; Rosa Chacón-Díaz; Claudio M Galarza-Maldonado; Antonio J Iglesias Gamarra; José Fernando Molina; Oscar Neira; Clóvis A Silva; Andrea Vargas Peña; José A Gómez-Puerta; Marina Scolnik; Guillermo J Pons-Estel; Michelle R Ugolini-Lopes; Verónica Savio; Cristina Drenkard; Alejandro J Alvarellos; Manuel F Ugarte-Gil; Alejandra Babini; André Cavalcanti; Fernanda Athayde Cardoso Linhares; Maria Jezabel Haye Salinas; Yurilis J Fuentes-Silva; Ana Carolina Montandon de Oliveira E Silva; Ruth M Eraso Garnica; Sebastián Herrera Uribe; Diana Gómez-Martín; Ricardo Robaina Sevrini; Rosana M Quintana; Sergio Gordon; Hilda Fragoso-Loyo; Violeta Rosario; Verónica Saurit; Simone Appenzeller; Edgard Torres Dos Reis Neto; Jorge Cieza; Luis A González Naranjo; Yelitza C González Bello; María Victoria Collado; Judith Sarano; Soledad Retamozo; María E Sattler; Rocio V Gamboa-Cárdenas; Ernesto Cairoli; Silvana M Conti; Luis M Amezcua-Guerra; Luis H Silveira; Eduardo F Borba; Mariana A Pera; Paula B Alba Moreyra; Valeria Arturi; Guillermo A Berbotto; Cristian Gerling; Carla A Gobbi; Viviana L Gervasoni; Hugo R Scherbarth; João C Tavares Brenol; Fernando Cavalcanti; Lilian T Lavras Costallat; Nilzio A Da Silva; Odirlei A Monticielo; Luciana Parente Costa Seguro; Ricardo M Xavier; Carolina Llanos; Rubén A Montúfar Guardado; Ignacio Garcia de la Torre; Carlos Pineda; Margarita Portela Hernández; Alvaro Danza; Marlene Guibert-Toledano; Gil Llerena Reyes; Maria Isabel Acosta Colman; Alicia M Aquino; Claudia S Mora-Trujillo; Roberto Muñoz-Louis; Ignacio García Valladares; María Celeste Orozco; Paula I Burgos; Graciela V Betancur; Graciela S Alarcón
Journal:  Ann Rheum Dis       Date:  2018-07-25       Impact factor: 19.103

4.  Evaluation of belimumab treatment in patients with systemic lupus erythematosus in a clinical practice setting: Results from a 24-month OBSErve study in Argentina.

Authors:  A Babini; A M Cappuccio; C Caprarulo; G Casado; A Eimon; H Figueredo; M A García; S Magri; P Mannucci; S Perez Rodriguez; B A Pons-Estel; E J Velozo; M Iglesias-Rodriguez; G Streger
Journal:  Lupus       Date:  2020-08-14       Impact factor: 2.911

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.